Invesco NASDAQ Next Gen 100 ETF
QQQJ - ETF AI Analysis
Top Page
Invesco NASDAQ Next Gen 100 ETF (QQQJ)
QQQJ, the Invesco NASDAQ Next Gen 100 ETF, has a solid overall rating that reflects a portfolio led by strong companies like NetApp, Steel Dynamics, Biogen, and United Airlines, which show healthy financial performance, positive earnings sentiment, and in several cases strong momentum or attractive valuations. These strengths are partly offset by weaker names such as Revolution Medicines, which faces ongoing losses and bearish trading trends, and by some holdings with high leverage or valuation concerns, creating risk if market conditions turn. The main risk factor is that several key holdings carry financial or valuation pressures, so the fund’s success depends on these companies continuing to execute well despite those headwinds.
QQQJ vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.17B
- Region
- North America
- Expense Ratio
- 0.15%
- Beta
- 1.07
- Issuer
- Invesco
- Inception Date
- Oct 13, 2020
- Dividend Yield
- 0.76%
- Asset Class
- Equity
- Index Tracked
- Nasdaq Next Generation 100 Index
QQQJ Summary
QQQJ is the Invesco NASDAQ Next Gen 100 ETF, which follows the Nasdaq Next Generation 100 Index. It focuses on the “next wave” of NASDAQ companies just below the famous NASDAQ-100, with a mix of technology, health care, and consumer businesses. Well-known holdings include eBay and Biogen. Investors might consider QQQJ if they want growth potential from emerging leaders while still getting diversification across many sectors. A key risk is that these growth-focused stocks can be more volatile, so the ETF’s value can go up and down sharply with changes in the market.
How much will it cost me?
This ETF has an expense ratio of 0.15%, which means you’ll pay about $1.50 per year for every $1,000 invested. That cost is slightly lower than the average stock ETF because it’s passively managed and simply tracks the Nasdaq Next Generation 100 Index instead of paying managers to pick individual stocks.
What would affect this ETF?
QQQJ could benefit if U.S. economic growth stays solid, technology and health care innovation remains strong, and investor interest in fast-growing NASDAQ companies like Natera, eBay, and Atlassian increases, especially in a stable or falling interest rate environment. On the other hand, higher interest rates, tighter regulations on tech or health care, or a downturn in U.S. growth and consumer spending could hurt many of its key sectors and top holdings, making the ETF more volatile.
QQQJ Top 10 Holdings
QQQJ is leaning into U.S. innovation, with rising names like Okta, NetApp, and Illumina helping power the fund as demand for cloud, cybersecurity, and genomic tools picks up. Natera and Biogen add more health-care punch, keeping performance on a generally upward track. On the flip side, Revolution Medicines has been lagging, and Kimberly-Clark looks more defensive, occasionally acting like a brake on this growth-heavy mix. Overall, the ETF is clearly tilted toward tech and health care, with a mostly U.S.-focused roster of next-gen contenders.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| eBay | 2.77% | $32.12M | $53.08B | 43.22% | 70Outperform | |
| Natera | 2.37% | $27.45M | $46.27B | 59.01% | 73Outperform | |
| Revolution Medicines | 1.90% | $22.04M | $37.27B | 167.61% | 52Neutral | |
| United Airlines Holdings | 1.83% | $21.18M | $35.51B | 12.49% | 74Outperform | |
| Biogen | 1.93% | $22.35M | $37.46B | 53.83% | 74Outperform | |
| Medline | 1.78% | $20.67M | $51.93B | -3.73% | ―― | |
| Kimberly Clark | 1.87% | $21.72M | $67.15B | 4.77% | 63Neutral | |
| NetApp | 1.83% | $21.25M | $35.62B | 65.48% | 76Outperform | |
| Steel Dynamics | 1.69% | $19.63M | $32.63B | 48.41% | 76Outperform | |
| Elbit Systems | 1.70% | $19.75M | ILS 107.06B | 48.23% | 73Outperform |
QQQJ Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QQQJ, the sentiment is Negative. The current price of 43.19 is below the 20-day moving average (MA) of 43.94, below the 50-day MA of 44.15, and above the 200-day MA of 42.16, indicating a neutral trend. The MACD of -0.24 indicates Positive momentum. The RSI at 44.70 is Neutral, neither overbought nor oversold. The STOCH value of 60.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QQQJ.
QQQJ Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $43.19 | $48.00(11.14% Upside) | $1.17B | 0.15% | 68Neutral | |
| $341.41 | $424.69(24.39% Upside) | $9.54B | 0.06% | 73Outperform | |
| $43.18 | $53.10(22.97% Upside) | $9.24B | 0.31% | 69Neutral | |
| $42.62 | $51.21(20.15% Upside) | $9.05B | 0.18% | 73Outperform | |
| $17.72 | $23.12(30.49% Upside) | $8.24B | 0.60% | 73Outperform | |
| $104.88 | $110.76(5.61% Upside) | $8.05B | 0.53% | 74Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| QQQJ | Invesco NASDAQ Next Gen 100 ETF | 43.19 | 7.76 | 21.91% | |
| VONE | Vanguard Russell 1000 ETF | 341.41 | 43.49 | 14.60% | |
| TCAF | T. Rowe Price Capital Appreciation Equity ETF | 43.18 | 5.25 | 13.84% | |
| FELC | Fidelity Enhanced Large Cap Core ETF | 42.62 | 5.86 | 15.93% | |
| QYLD | Global X NASDAQ 100 Covered Call ETF | 17.72 | 2.30 | 14.89% | |
| FTCS | First Trust Capital Strength ETF | 104.88 | 14.95 | 16.62% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
